releases: http://upton.house.gov/news/documentsingle.aspx?DocumentID=401306
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| http://upton.house.gov/news/documentsingle.aspx?DocumentID=401306 | Upton: H.R. 3 means fewer cures for patients | 2019-12-10 | 2019 | 2019-12 | Republican | House | MI | Fred Upton | U000031 | upton.house.gov | legacy | Washington, D.C. Today, U.S. Rep. Fred Upton spoke at today's leadership press conference to discuss his opposition to H.R. 3, the Lower Drug Costs Now Act, and his support for the bipartisan alternative, H.R. 19, the Lower Costs, More Cures Act. As the author of the historic 21st Century Cures Act, Upton expressed his concerns with how H.R. 3 would stifle innovation, leading to fewer life-saving cures and drugs. Click hereto view Upton's remarks. Full remarks: Well this week marks the third anniversary of the enactment of 21st Century Cures that President Obama signed. The bill of course passed the House 392-26, strongly bipartisan in both the House and Senate. And one of the things that, the main focal points of what it did was expedite the approval of drugs and devices, and now three years later we've seen some tremendous successes. I was with a young girl last week in a wheelchair who has SMA, that's spinal muscular atrophy, its often fatal for young children. She had been on a drug just barley for 15 days and already she was getting muscle, she was able to move her head back and forth for the first time in more than a decade. Last week, I met with some folks that we're very excited about. A new stage 3/stage 4 pancreatic cancer drug that has been enormously successful in the first number of trials and, because of Cures, if it is successful, could be the first drug that actually deals with this and gets to market years faster than perhaps it otherwise would have. We've seen some success on the Alzheimer's drugs, last week in USA today, the headline, Autism Research Takes a Step Forward. All of these happen because of what we did on 21st Century Cures. The Democratic bill, H.R. 3, would stifle the innovation, and whether it's the CEA or the CBO, they all talk about drugs that will not likely make it to market for years, slower than it otherwise would have. Our substitute would continue the innovation surge we have seen because of 21st Century Cures and be able to find the cures for the diseases that really impact every family that's there, which is one of the reason why H.R. 19 is an important substitute that we would like to see be able to be offered, and debated, and voted on instead of H.R. 3, which really has no chance of either getting through the Senate or ever reaching the President's desk and therefore denying Americans the research and ability to find cures for these diseases. ### | 1 | 2026-03-30T12:14:52Z | 2026-03-30T12:14:52Z |